Drawing of heart diagram with parts of the heart labeled with letters

Comprehensive Solutions for Heart Failure Management

Breakthrough technologies with proven clinical outcomes

An estimated 5.7 million American adults are affected by heart failure (HF).1 Every year in the United States, approximately 1 million patients are hospitalized with a primary discharge diagnosis of HF, with HF the leading cause of hospitalizations for adults aged 65 or older.2 The cost of treating HF in the U.S. is expected to reach $70 billion by 2030.3 In 2012, Medicare’s average cost per beneficiary with a diagnosis of heart failure exceeded $33,000 per year, approximately three times the cost of an average beneficiary.4

While the Centers for Medicare and Medicaid Services (CMS) has developed ongoing and planned reimbursement reform programs, we have dedicated our efforts to providing you with the broadest scope of technologically innovative, clinically proven and outcome-driven solutions for better heart failure management. The benefits of frequent insight and early intervention that our technologies can give you are matched only by our ability to increase efficacy while decreasing the economic cost associated with cardiovascular care.


Patient in front of the Golden Gate Bridge

Heart Failure Management Portfolio

Abbott innovates and challenges the status quo, offering game-changing heart failure technologies to help better manage the economic and treatment challenges associated with heart failure. Our results include innovative and effective quadripolar technology, MultiPoint™ pacing, the CardioMEMS™ HF System and the HeartMate II™ and HeartMate 3™ Left Ventricular Assist Devices.

Related Portfolio

Learn about our other advanced portfolio designed to improve the treatment of heart failure while reducing costs for all.

Remote Monitoring Portfolio

Our remote monitoring portfolio, with Merlin.net™ Patient Care Network and Merlin@home™ wireless transmitter can help you optimize workflow, support informed clinical decisions and deliver efficient, comprehensive care.

Improving Outcomes With the CardioMEMS™ HF System

43% reduction in HF hospitalizations

Directly monitoring PA pressure with the CarioMEMS™ HF System not only notifies you if a patient’s heart failure is worsening, but also allows you to intervene earlier, adjusting medication or making other treatment changes

In a retrospective analysis of the CHAMPION clinical data for HFrEF patients already on guideline-directed medical therapy, pulmonary artery pressure guided management reduced HF hospitalizations by 43 percent.7

See more CardioMEMS™ HF System evidence.

Additional MPP Pacing Options

Providing Additional CRT Options With MultiPoint™ Pacing

MultiPoint™ pacing technology, a feature of the Quadra Assura MP™ cardiac resynchronization therapy defibrillator (CRT-D) and the Quadra Allure MP™ cardiac resynchronization pacemaker (CRT-P), which pair with the Quartet™ Quadripolar LV lead, lets you pace from two left ventricular (LV) sites. Pacing from two LV sites is designed to capture more tissue and provide additional CRT options to change:

  • Pattern of depolarization
  • Engagement of areas around scar tissue
  • Hemodynamics
  • Resynchronization

Post-hoc subanalysis of the recent MPP™ technology U.S. IDE study yielded clinical evidence for improved outcomes with MPP™ technology.8 See the MPP™ technology U.S. IDE evidence, along with clinical evidence for our other heart failure solutions.

Clinical Leadership in HF Quality of Life and Overall Survival9,10

Our vision is to provide a continuum of care and transform the treatment of heart failure and other expensive epidemic diseases by creating innovative technologies that are clinically effective for patients and cost effective for hospitals. We back our innovation with clinical leadership by building a body of evidence that supports the improved outcomes and exceptional quality of our first-to-market therapies.

See Clinical Evidence
Physicians looking at a clipboard

Economically Improving CRT Systems

Our effective, clinically proven solutions can help you reduce the cost of managing heart failure. One example is our quadripolar technology. Clinical studies demonstrate that quadripolar technology lowered costs and reduced hospitalizations when compared to bipolar CRT systems.

  • 53% lower hospitalization rate due to heart failure and left ventricular lead surgical revision9
  • 87% lower hospitalization costs in the first 100 days post-implant10
  • Overall, there is a 98% probability that patients using quadripolar technology will cost less than patients using bipolar systems9
53% lower hospitalization rate due to heart failure and left ventricular lead surgical revision87% lower hospitalization costs in the first 100 days post-implant98% probability that patients using quadripolar technology will cost less than patients using bipolar systems


*At the 6-month primary endpoint in the MOMENTUM 3 trial. (MOMENTUM 3 = Multicenter Study of Maglev Technology in Patients Undergoing Mehcanical Circulatory Support Therapy with HeartMate 3 LVAD.)
**As defined by zero incidence of pump thrombosis in the MOMENTUM 3 trial at 6 months.
1. Mozaffarian, D., Benjamin, E. J., Go, A., A., Arnett, D. K., Blaha, M. J., Cushman, M., ... Truner, M. B. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, (2015). Heart disease and stroke statistics—2016 update: A report from the American Heart Association. Circulation, 132, e1-e323. http://dx.doi.org/10.1161/CIR.0000000000000350
2. Adams, K. F. Jr., Fonarow, G. C., Emerman, C. L., LeJemtel, T. H., Constanzo, M. R., Abraham, W. T., … Horton, D. P., & ADHERE Scientific Advisory Committee and Investigators. (2005). Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal, 149(2), 209-216. http://dx.doi.org/10.1016/j.ahj.2004.08.005
3. American Heart Association. (2013, April 24). Costs to treat heart failure expected to more than double by 2030. Retrieved from http://newsroom.heart.org/news/costs-to-treat-heart-failure-expected-to-more-than-double-by-2030.
4. Centers for Medicare & Medicaid Services. Chronic Conditions Among Medicare Beneficiaries Chartbook: 2012 Edition. Retrieved from http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Chronic-Conditions/Downloads/2012Chartbook.pdf. Accessed April 23, 2014.
5. Abraham, W. T., Adamson, P. B., Bourge, R. C., Costanzo, M. R., Stevenson, L. W., Strickland, W., … Yadav, J, S, & CHAMPION Trial Study Group. (2011). Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. The Lancet, 377(9766), 658-666. http://dx.doi.org/ 10.1016/S0140-6736(11)60101-3
6. Mehra, M. R., Yoshifumi, N., Uriel, N., Goldstein, D. J., Cleveland, J. C. Jr., Colombo, Paolo C., … Salerno, C. for the MOMENTUM 3 Investigators. A fully magnetically levitated circulatory pump for advanced heart failure. (2016, November 16). The New England Journal of Medicine, 376,440-50. http://dx.doi.org/10.1056/NEJMoa1610426
7. Abraham, W. T., Adamson, P. B., Stevenson, L. W., Costanzo, M. R., Bourge, R. C., Bauman, J., … Yadav, J. (2015, May). Pulmonary artery pressure management in heart failure patients with cardiac resynchronization therapy or implantable cardioverter defibrillator devices significantly reduces heart failure hospitalizations and mortality above and beyond background guide-directed medical therapy. Presented at the meeting of the Heart Rhythm Society, Boston, MA.
8. Tomassoni, G., Baker II, J., Corbisiero, R., Love, C., Martin, D., Sheppard, R., Worley, S., Varma, N., & Niazi, I. (2016, May). Safety and efficacy of multipoint pacing in cardiac resynchronization therapy: The MultiPoint Pacing (MPP) IDE Study. Presented at the meeting of the Heart Rhythm Society, San Francisco, CA, LBCT 01-03.
9. Forleo, G. B., Mantica, M., Di Biase, L., Panattoni, G., Della Rocca, D. G., Papavasileiou, L. P., … Romeo, F. (2012). Clinical and procedural outcome of patients implanted with a quadripolar left ventricular lead: Early results of a prospective multicenter study. Heart Rhythm, 9(11), 1822-1828. http://dx.doi.org/10.1016/j.hrthm.2012.07.021
10. Forleo, G. B., Panattoni, G., Bharmi, R., Dalal, N., Pollastrelli, A., Della Rocca, D., … & Romeo, F. (2014, May). Hospitalization rates and associated cost analysis of quadripolar versus bipolar CRT-D: A comparative analysis of single-center prospective Italian registry. Presented at the meeting of the Heart Rhythm Society, San Francisco, CA.

Orange 24 surrounded by headset, represents "Place an order"

Contact Customer Service

Our customer service experts can help with your product orders or questions.